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Stability-mediated epistasis constrains the 
evolution of an influenza protein
Lizhi Ian Gong1, Marc A Suchard2, Jesse D Bloom1,3*
1Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle, United 
States; 2Departments of Biomathematics, Biostatistics, and Human Genetics, 
University of California, Los Angeles, Los Angeles, United States; 3Computational 
Biology Program, Fred Hutchinson Cancer Research Center, Seattle, United States
Abstract John Maynard Smith compared protein evolution to the game where one word is 
converted into another a single letter at a time, with the constraint that all intermediates are words: 
WORD→WORE→GORE→GONE→GENE. In this analogy, epistasis constrains evolution, with some 
mutations tolerated only after the occurrence of others. To test whether epistasis similarly 
constrains actual protein evolution, we created all intermediates along a 39-mutation evolutionary 
trajectory of influenza nucleoprotein, and also introduced each mutation individually into the parent. 
Several mutations were deleterious to the parent despite becoming fixed during evolution without 
negative impact. These mutations were destabilizing, and were preceded or accompanied by 
stabilizing mutations that alleviated their adverse effects. The constrained mutations occurred at 
sites enriched in T-cell epitopes, suggesting they promote viral immune escape. Our results paint a 
coherent portrait of epistasis during nucleoprotein evolution, with stabilizing mutations permitting 
otherwise inaccessible destabilizing mutations which are sometimes of adaptive value.
DOI: 10.7554/eLife.00631.001
Introduction
Epistasis can play a key role in evolution, such as by constraining accessible evolutionary pathways 
(Weinreich et al., 2005; Kryazhimskiy et al., 2011) and increasing the role of contingency in adaptation 
(Blount et al., 2008; Bridgham et al., 2009). One of the simplest types of epistasis is that which occurs 
between mutations within a single protein. That such epistasis is common has long been considered 
self-evident–for example, in their seminal 1965 analysis of protein evolution, Emile Zuckerkandl and Linus 
Pauling wrote, “Of course … the functional effect of a given single substitution will frequently depend 
on the presence or absence of a number of other substitutions (Zuckerkandl and Pauling, 1965).” But 
although numerous laboratory evolution and site-directed mutagenesis experiments have demonstrated 
that mutations can in principle exhibit strong epistatic interactions (Bershtein et al., 2006; Bloom et al., 
2006; Lunzer et al., 2010; Salverda et al., 2011), surprisingly little is known about the actual role of 
epistasis in natural protein evolution. A few studies have reconstructed naturally occurring mutations 
involved in antibiotic resistance or steroid-receptor ligand specificity (Wang et al., 2002; Weinreich 
et al., 2006; Ortlund et al., 2007; Bridgham et al., 2009) and found strong epistatic interactions. 
However, these studies have focused on small numbers of mutations pre-selected for analysis due to 
their putative adaptive role, and in most cases the actual temporal order of mutations is unknown.
As a result, many basic questions remain without clear answers: What is the prevalence of epistasis 
during protein evolution? How does epistasis arise from an evolutionary process that is conceived as 
proceeding through the incremental accumulation of mutations? And is it possible to coherently 
understand epistasis in terms of the underlying protein biophysics?
An experimental approach to address these questions is suggested by John Maynard Smith’s 
classic analogy between protein evolution and the game where the goal is to convert one word 
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into another a single letter at a time passing only through intermediates that are also words (Maynard 
Smith, 1970):
.→ → → →WORD WORE GORE GONE GENE
Implicit in this analogy is the idea that epistasis constrains evolution—for example, the original 
parent sequence does not tolerate three of the four eventual changes, as GORD, WERD and WOND 
are not words. We sought to similarly test for epistasis in actual protein evolution by reconstructing an 
extended natural evolutionary trajectory, and then also introducing each mutation individually into the 
original parent (Figure 1). While this experimental strategy is not guaranteed to find every possible 
epistatic interaction, it will systematically identify all mutations that have different effects in the original 
parent and the evolutionary intermediates in which they actually occurred. The experimental strategy 
in Figure 1 also offers the possibility of determining how epistatically interacting mutations were ac-
tually fixed—for example through sequential functional intermediates as posited by Maynard Smith, or 
by the simultaneous or closely coupled fixation of several individually deleterious mutations (Kimura, 
1985; Meer et al., 2010).
The experiment outlined in Figure 1 requires a protein for which it is possible both to reconstruct 
the natural evolution and to assay for the functions that contribute to biological fitness. Human H3N2 
influenza A virus is exceptionally suited to the first requirement, as the extensive availability of contem-
porary and historical sequences enables the detailed reconstruction of evolutionary trajectories. We 
focused on the 498-residue nucleoprotein (NP). Although NP’s evolution is less rapid and medically 
infamous than that of its surface counterparts hemagglutinin and neuraminidase, NP still accumulates 
roughly one amino-acid substitution per year (Rambaut et al., 2008). Crucially for our experiment, 
eLife digest During evolution, the effect of one mutation on a protein can depend on whether 
another mutation is also present. This phenomenon is similar to the game in which one word is 
converted to another word, one letter at a time, subject to the rule that all the intermediate steps 
are also valid words: for example, the word WORD can be converted to the word GENE as follows: 
WORD→WORE→GORE→GONE→GENE. In this example, the D must be changed to an E before the 
W is changed to a G, because GORD is not a valid word.
Similarly, during the evolution of a virus, a mutation that helps the virus evade the human 
immune system might only be tolerated if the virus has acquired another mutation beforehand. This 
type of mutational interaction would constrain the evolution of the virus, since its capacity to take 
advantage of the second mutation depends on the first mutation having already occurred.
Gong et al. examined whether such interactions have indeed constrained evolution of the 
influenza virus. Between 1968 and 2007, the nucleoprotein—which acts as a scaffold for the 
replication of genetic material—in the human H3N2 influenza virus underwent a series of 39 
mutations. To test whether all of these mutations could have been tolerated by the 1968 virus, 
Gong et al. introduced each one individually into the 1968 nucleoprotein. They found that several 
mutations greatly reduced the fitness of the 1968 virus when introduced on their own, which 
strongly suggests that these ‘constrained mutations’ became part of the virus’s genetic makeup as a 
result of interactions with ‘enabling’ mutations.
The constrained mutations decreased the stability of the nucleoprotein at high temperatures, 
while the enabling mutations counteracted this effect. It may, therefore, be possible to identify 
enabling mutations based on their effects on thermal stability. Intriguingly, the constrained 
mutations helped the virus overcome one form of human immunity to influenza, suggesting that 
interactions between mutations might limit the rate at which viruses evolve to evade the immune 
system.
Overall, these results show that interactions among mutations constrain the evolution of the 
influenza nucleoprotein in a fashion that can be largely understood in terms of protein stability. If 
the same is true for other proteins and viruses, this work could lead to a deeper understanding of 
the constraints that govern evolution at the molecular level.
DOI: 10.7554/eLife.00631.002
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NP’s primary function—serving as a scaffold for viral RNA during transcription and genome packaging 
(Portela and Digard, 2002; Ye et al., 2006)—occurs within the interior of infected cells, and so is 
probably fairly authentically represented in tissue-culture assays.
NP is also a target of cytotoxic T lymphocytes (CTLs), and so is under continual pressure for change 
in CTL epitopes (Berkhoff et al., 2004, 2007; Valkenburg et al., 2011)—a pressure partially coun-
tered by the fact that some of these epitopes are under functional constraint (Rimmelzwaan, et al., 
2004a; Berkhoff et al., 2005, 2006). CTL selection in influenza is thought to be weaker than antibody 
selection on the viral surface proteins, and so much of NP’s evolution is shaped by stochastic forces 
such as population bottlenecks and hitchhiking with antigenic mutations in the surface proteins 
(Rambaut et al., 2008; Bhatt et al., 2011)—stochastic forces that in some cases can also accelerate 
the fixation CTL escape mutations (Gog et al., 2003). Our experiments do not measure these com-
plexities of immune pressure as they do not include CTL selection, but as described later in this paper, 
existing data enable us to identify adaptive CTL-escape mutations.
In the work reported here, we use the strategy in Figure 1 to synthesize information about influ-
enza’s natural evolution with our own experiments to examine epistasis in NP evolution. We find that 
epistasis constrains both the sequence evolution and ongoing adaptation of NP, and that the mecha-
nistic basis for most of this epistasis can be understood in remarkably simple terms.
Results
Several mutations are under strong epistatic constraint
We focused on the evolutionary trajectory separating NPs from two human H3N2 strains isolated 39 
years apart, A/Aichi/2/1968 and A/Brisbane/10/2007 (Figure 2). To map this trajectory, we developed 
a probabilistic technique to estimate the posterior distribution of mutational events (Minin and 
Suchard, 2008; O’Brien et al., 2009) and, original to this work, their time-orderings along an unknown 
phylogenetic tree within the BEAST software package (Drummond et al., 2012). Each sample from 
this posterior distribution represents a mutational path from Aichi/1968 to Brisbane/2007, which in 
turn can be represented as a directed graph through protein sequence space (Figure 2—figure sup-
plement 1). Summarizing these graph samples effectively integrates over uncertainty in the tree and 
substitution process, and yields the marginal posterior distribution of the evolutionary trajectory from 
Aichi/1968 to Brisbane/2007 (Figure 2). The most probable trajectory consists of 39 mutational steps 
at 33 sites (5 mutations revert; 1 site mutates to two identities). The fact that NP sequences are avail-
able for every year since 1968 allows us to reconstruct the trajectory with remarkable precision: there 
are >1046 possible orderings of 39 mutations, yet we can confidently identify the sequences of 25 of 
the evolutionary intermediates; the remainder fall along regions of the trajectory where two or more 
mutations occurred in an unknown order (Figure 2).
A B
Figure 1. Outline of experiment designed to parallel Maynard Smith’s analogy. The actual evolutionary trajectory 
involves the accumulation of mutations, and consists of a series of evolutionary intermediates. We recreate and 
experimentally assay each of these evolutionary intermediates. We also introduce each mutation individually into 
the original parent sequence, and experimentally assay these single mutants. If Maynard Smith is correct, each of 
the naturally occurring evolutionary intermediates should be a functional protein. However, some of the single 
mutants could exhibit impaired function if there is significant epistasis among mutations along the evolutionary 
trajectory.
DOI: 10.7554/eLife.00631.003
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A B
Figure 2. Inferred evolutionary trajectory. (A) Evolutionary trajectory through protein sequence space from Aichi/1968 to Brisbane/2007 NP. Each circle 
represents a unique inferred sequence, with areas and intensities proportional to the probability that sequence was part of the evolutionary trajectory 
(Figure 2—figure supplement 1). Mutations for which the parent and descendent are clearly resolved are in black; mutations that occurred in an 
unknown order are in red. High-confidence evolutionary intermediates have numeric labels. The estimated date of occurrence of each mutation is shown 
in Figure 2—figure supplement 2. (B) Phylogenetic tree of the human H3N2 NPs from 1968 to 2011 that were used to infer the evolutionary trajectory. 
The lines of descent connecting Aichi/1968 and Brisbane/2007 to their common ancestor are in black. Data and computer code are provided in 
Figure 2—source code 1.
DOI: 10.7554/eLife.00631.004
The following source code and figure supplements are available for figure 2:
Source code 1. The sequence data and source code used to generate the evolutionary trajectory and phylogenetic tree. 
DOI: 10.7554/eLife.00631.005
Figure supplement 1. Construction of the evolutionary trajectory. 
DOI: 10.7554/eLife.00631.006
Figure supplement 2. Dates at which mutations fixed along the evolutionary trajectory in Figure 2A. 
DOI: 10.7554/eLife.00631.007
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We created plasmids encoding each of the high-confidence protein intermediates along the trajec-
tory, using the same codons found in the natural sequences but not introducing any of the synonymous 
mutations that occurred during this timeframe. We used a mini-replicon system to assess the transcrip-
tional activity of each NP in combination with polymerase proteins (PB2, PB1, PA) from the human 
H3N2 strain A/Nanchang/933/1995 (Figure 3—figure supplement 1). All evolutionary intermediates 
exhibited high activity (Figure 3A), supporting Maynard Smith’s notion that evolution proceeds 
through functional sequences.
We then introduced each mutation individually into the parent Aichi/1968 NP and measured its 
effect on activity (Figure 3B). Most single mutants were highly functional, but three (L259S, R384G, 
V280A) exhibited large decreases in activity. These three mutations are also deleterious in the back-
ground of polymerase proteins from Aichi/1968 and Brisbane/2007 (Figure 3—figure supplement 3), 
suggesting that the deleterious effect is intrinsic to NP itself.
Because RNA transcription is essential for influenza replication, impaired activity should be devas-
tating to viral fitness. To confirm this, we used reverse genetics (Hoffmann et al., 2000) to generate 
GFP-carrying viruses (Bloom et al., 2010) with the polymerase genes from Nanchang/1995 and the 
remaining genes from the lab-adapted A/WSN/1933 (H1N1) strain (Figure 3—figure supplement 2). 
Viruses with the parent (Aichi/1968) or final (Brisbane/2007) NP grew to comparably high titers in 
tissue culture (Figure 3C), but growth of the three transcriptionally impaired mutants was dramatically 
lower (>1000-fold lower for L259S and R384G, and >20-fold lower for V280A). However, we observed 
good growth of the first high-confidence evolutionary intermediates in which these mutations were 
actually fixed (Figure 3C).
Effects of the epistatically constrained mutations in the evolutionary 
intermediates in which they occurred
To understand how the three individually deleterious mutations fixed along the line of descent without 
a substantial fitness cost, we examined the evolutionary trajectory. L259S fixed in an unknown order 
with another mutation (N334H) in an evolutionary intermediate that we have labeled Step 10 (Figure 4A). 
L259S is deleterious to activity and growth in both Aichi/1968 and Step 10, while N334H has no 
major effect in either background (Figure 4A). But N334H rescues the deleterious effect of L259S in 
both Aichi/1968 and Step 10, indicating that fixation of L259S was enabled by N334H. We cannot 
determine the order of these two mutations during the evolution of the virus: they could have occurred 
simultaneously, or one could have preceded the other by a sufficiently small amount of time that no 
influenza isolates were sequenced in the intervening time period.
The next individually deleterious mutation, R384G, fixed in Step 21 in an unknown order with sev-
eral other mutations (Figure 4B). Immediately prior to this, the individually deleterious mutation L259S 
reverted in the transition from Step 20 to Step 21. R384G is deleterious to activity and growth in both 
Aichi/1968 and Step 20 (Figure 4B). However in Step 21, the deleterious effect on activity disappears 
while that on growth diminishes, indicating that reversion of L259S alleviates the impact of R384G. The 
further addition of E375G to Step 21 containing R384G eliminates the remaining growth impairment—
but E375G alone fails to rescue R384G in the background of Aichi/1968 (Figure 4B). Note that E375G 
has also been previously reported to partially compensate for R384G in slightly different genetic back-
grounds (Rimmelzwaan et al., 2004a). Fixation of R384G was therefore partially enabled by the pre-
ceding reversion of L259S, with further assistance from E375G. S259L clearly preceded R384G, but we 
are unable to resolve whether the second enabling mutation (E375G) occurred before, after, or simul-
taneously with R384G.
The final individually deleterious mutation, V280A, fixed in Step 35. Although V280A is deleterious 
in Aichi/1968, it has no negative impact in Step 35 (Figure 4C). M136I, which immediately preceded 
V280A in the natural evolution, mostly rescues its deleterious effect in the background of Aichi/1968 
(Figure 4C). Therefore, V280A was enabled by mutations (including M136I) that occurred prior to its 
own fixation.
Most of the mutational effects are mediated by protein stability
What is the mechanistic explanation for these mutational effects? None of the identified epistatically 
interacting residues are in contact in the monomeric or known oligomeric NP crystal structures (Ye et al., 
2006, 2012; Ng et al., 2008), nor are any of them in the protein’s RNA-binding groove (Figure 5 
and Figure 5—figure supplement 1). We therefore hypothesized that the individually deleterious 
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Gong et al. eLife 2013;2:e00631. DOI: 10.7554/eLife.00631 6 of 19
Research article
A
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Figure 3. Three mutations are strongly deleterious when introduced individually into the parent Aichi/1968 NP, despite eventually becoming fixed along 
the evolutionary trajectory without apparent negative effect. (A) The transcriptional activity for the high-confidence evolutionary intermediates, quanti-
fied using a GFP reporter (Figure 3—figure supplement 1). Activity is scaled so that the parent Aichi/1968 NP has an activity of one. The numeric labels 
of the evolutionary intermediates match those used in Figure 2A. (B) The change in activity caused by introducing each mutation individually into the 
parent Aichi/1968 NP. The deleterious effects on activity caused by L259S, R348G, and V280A are not caused by the genetic background of influenza 
polymerase proteins, as these three mutants are impaired regardless of whether the polymerase proteins are derived from Nanchang/1995, Aichi/1968, 
or Brisbane/2007 (Figure 3—figure supplement 3). (C) All three of the individual mutations that reduce activity also impair growth, yet there is no defect 
in the growth of viruses carrying the NPs of the first high-confidence evolutionary intermediates in which these individually deleterious mutations were 
actually fixed. Viral growth is quantified as described in Figure 3—figure supplement 2. Numerical data are in Figure 3—source data 1–3.
DOI: 10.7554/eLife.00631.008
The following source data and figure supplements are available for figure 3:
Source data 1. Summary of transcriptional activity data (mean and standard error) for all variants from this study. 
DOI: 10.7554/eLife.00631.009
Source data 2. Summary of viral growth data (mean and standard error) for all variants for which this property was measured in this study. 
DOI: 10.7554/eLife.00631.010
Figure 3. Continued on next page
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Source data 3. Transcriptional activity data in the alternative polymerase genetic backgrounds shown in Figure 3—figure supplement 3. 
DOI: 10.7554/eLife.00631.011
Figure supplement 1. Schematic of NP transcriptional activity assay. 
DOI: 10.7554/eLife.00631.012
Figure supplement 2. Schematic of viral growth assay. 
DOI: 10.7554/eLife.00631.013
Figure supplement 3. Effects of key NP mutations on transcriptional activity in different polymerase genetic background of the viral polymerase 
genes. 
DOI: 10.7554/eLife.00631.014
Figure 3. Continued
mutations might destabilize NP, and that the epistasis might be mediated by counterbalancing stabiliz-
ing mutations. This hypothesis is consistent with the fact that N334H rescues L259S, and reversion of 
L259S in turn partially rescues R384G, despite the lack of physical contact among these residues.
We began by pairing N334H with each of the individually deleterious mutations in the background 
of the parent Aichi/1968 NP. N334H rescues activity for each of these mutations (Figure 6A). N334H 
also rescues growth for L259S and V280A, and largely rescues growth for R384G (Figure 6B). To test 
if this rescue was related to in vivo protein levels, we quantified NP in transfected human cells (Figure 
6C,D). The parent Aichi/1968 NP and its N334H mutant were present at comparably high levels, but 
levels were markedly reduced for variants carrying each of the three individually deleterious mutations. 
Addition of N334H to these mutants restored wild-type protein levels, indicating that N334H can 
counteract the decrease in protein levels associated with the individually deleterious mutations.
To see if these changes in in vivo protein levels correlated with global protein stability, we purified 
the NP variants with an additional mutation in the tail loop (Ye et al., 2006) that enabled us to obtain 
monomeric RNA-free protein that exhibited the expected alpha-helical circular-dichroism spectrum 
(Figure 6—figure supplement 2). All NP variants exhibited similar circular-dichroism spectra (Figure 
6—figure supplement 3) and unfolded with a single cooperative transition (Figure 6—figure supple-
ments 4–6), allowing us to determine melting temperatures (Tm) for irreversible thermal denaturation. 
The three individually deleterious mutations were all destabilizing, with changes in melting tempera-
tures (ΔTm) relative to the parent Aichi/1968 NP that ranged from −3.6°C to −4.9°C. N334H was stabi-
lizing (ΔTm of 4.4°C), and adding N334H to each of the individual destabilized mutants restored their 
stability to roughly wild-type values (Figure 6E). M136I is also modestly stabilizing, and partially res-
cues all three individually deleterious mutations (Figure 6—figure supplements 4–7). The final 
Brisbane/2007 NP contains two of the three identified destabilizing mutations (L259S reverts) and 
both of the identified stabilizing mutations—combining all four mutations in the parental Aichi/1968 
background gives wild-type levels of activity (Figure 6—figure supplement 8).
These results suggest that most of the epistasis that we identified during NP’s evolution is due to 
counterbalancing stabilizing and destabilizing mutations. To obtain a more complete portrait, we 
measured the stabilities of all of the resolved evolutionary intermediates (Figure 6—figure supple-
ments 4–6). Figure 7A shows the correlation between activity and stability for all NP variants for which 
both properties were measured. For variants with melting temperatures exceeding 43°C, activity is 
independent of stability—changes in stability above this threshold are neutral with respect to activity. 
But once stability begins to fall below 43°C, there is a rapid decline in activity. A similar pattern is 
observed in the correlation between stability and viral growth, with growth declining precipitously 
once stability drops below 43°C (Figure 7B). The exception to this relationship is that variants contain-
ing R384G without E375G exhibit reduced growth even when they possess adequate stability and 
activity (Figures 4B, 7A,B). E375G is modestly destabilizing (ΔTm = −1.0°C), and so epistatically inter-
acts with R384G by a mechanism other than protein stability. E375G and R384G induce opposite 
charge changes and occur on the same surface of NP (Figure 5 and Figure 7—supplement figure 
1)—we hypothesize that maintenance of the electrostatic charge on this surface might be important 
for NP’s interaction with some partner late in the viral life cycle after RNA transcription is complete.
This caveat about R384G and E375G notwithstanding, it is striking that we can explain all of the 
other observed mutational effects simply in terms of protein stability. Figure 7C shows the trajec-
tory of stability during NP’s evolution. The parent Aichi/1968 is only marginally more stable than the 
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A B C
Figure 4. Effects of the individually deleterious mutations in the evolutionary intermediates in which they 
occurred. (A) L259S impairs the transcriptional activity and viral growth of both the parent Aichi/1968 and the 
evolutionary intermediate Step 10, but is rescued by N334H in both backgrounds. N334H alone has little effect 
on activity or growth in either background. The actual evolutionary trajectory involved the fixation of L259S 
and N334H in an unknown order. (B) R384G impairs activity and ablates growth of Aichi/1968, but has no effect 
on activity and a reduced adverse effect on growth in the high-confidence evolutionary intermediate (Step 21) 
in which it and several other mutations occurred in an unknown order. Addition of E375G to Step 21 with 
R384G fully rescues viral growth, but E375G alone worsens the impact of R384G. The reversion of L259S that 
preceded Step 21 plays an important role in enabling R384G, as the evolutionary intermediate without this 
reversion (Step 20) is more negatively affected by R384G. (C) V280A is deleterious in Aichi/1968 but not in the 
Step 35 evolutionary intermediate in which it actually occurred. M136I, which precedes V280A, largely rescues 
its effect.
DOI: 10.7554/eLife.00631.015
minimal threshold where activity and viral growth begin to suffer. For this reason, the three destabiliz-
ing mutations L259S, R384G, and V280A are highly deleterious to Aichi/1968. During NP’s evolution, 
stability fluctuates as the protein fixes stabilizing and destabilizing mutations. Each of the three desta-
bilizing mutations that we identified as being under epistatic constraint is closely associated with a 
stabilizing mutation. The stabilizing M136I preceded the destabilizing V280A, and provided a stability 
cushion to eliminate V280A’s otherwise deleterious effect (Figures 4C, 7C). The stabilizing S259L pre-
ceded the destabilizing R384G, and was necessary (in conjunction with E375G) to alleviate R384G’s 
otherwise deleterious effect (Figures 4B, 7C). The stabilizing N334H occurred in close temporal prox-
imity to the destabilizing L259S and fully counteracts L259S’s otherwise deleterious effect (Figures 4B, 
7C)—although in this case there is insufficient natural sequence data to determine which of these 
mutations occurred first (it is also possible that they occurred simultaneously).
The epistatically constrained mutations contribute to viral  
immune escape
The aforementioned results illuminate the evolutionary steps that gave rise to the fixation of the individ-
ually deleterious destabilizing mutations, but they do not provide any indication of what forces may have 
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driven this fixation. The destabilizing mutations 
could have been fixed stochastically by genetic drift 
or hitchhiking, or they could have been directly 
favored by selection for viral immune escape. As 
discussed in the Introduction, NP is a target of 
CTLs, and mutations in CTL epitopes benefit influ-
enza by helping it evade immune memory that 
accumulates in the human population (Berkhoff 
et al., 2007; Valkenburg et al., 2011).
We began by searching the literature for exper-
imentally validated human CTL epitopes in NP. All 
three destabilizing mutations occur in character-
ized epitopes (DiBrino et al., 1995; Voeten et al., 
2000; Rimmelzwaan et al., 2004b; Berkhoff 
et al., 2007; Assarsson et al., 2008; Alexander 
et al., 2010; Cheung et al., 2012), and mutations 
at two of these sites have been shown to reduce 
CTL recognition (Voeten et al., 2000; Berkhoff 
et al., 2004; Rimmelzwaan et al., 2004b; 
Berkhoff et al., 2007; Figure 8—source data 1).
To test if the epistatically constrained muta-
tions are in more epitopes than expected by 
chance, we considered two approaches to com-
prehensively identify epitopes in NP: mining of a 
database of literature-characterized epitopes 
(Vita et al., 2010), and computational prediction 
of epitopes from protein sequence (Stranzl et al., 
2010). The first approach has the advantage of 
only identifying experimentally validated epitopes, 
but the disadvantage that this set of epitopes is 
subject to unknown biases due to experimental 
choices about HLA types and viral strains. 
Computational prediction has the advantage of 
being unbiased with respect to HLA types and 
viral strains, but the disadvantage that the predic-
tions may not be accurate.
As it turns out, both approaches give the same 
result—the three epistatically constrained muta-
tions are significantly enriched in CTL epitopes 
relative to all sites in NP and to the set of sites that experienced substitutions along the evolutionary 
trajectory (Figure 8 and Figure 8—figure supplement 2). These three destabilizing mutations are thus 
disproportionately important for viral immune escape, and may have been favored by selection for this 
property (a dN/dS test [Murrell et al., 2013] is inconclusive, probably due to lack of sequence data; 
Figure 8—figure supplement 3 and Figure 8—source code 2). Stability-mediated epistasis therefore 
constrains the adaptive process of CTL escape as well as the sequence evolution of NP. The destabiliz-
ing CTL-escape mutations L259S, R384G, and V280A were inaccessible to NP during much of its evo-
lutionary trajectory, but were fixed after stabilizing mutations made the protein permissive to their 
occurrence.
Discussion
Our results paint a remarkably coherent picture of epistasis in NP evolution. We identified three muta-
tions that are strongly deleterious to the original parent, yet were eventually fixed without adverse 
effect. All three mutations decrease NP’s thermal stability. This decreased stability reduces in vivo 
protein levels, in turn reducing total transcriptional activity and viral growth. On the other hand, stabi-
lizing mutations have little effect on protein levels, activity, or growth in the background of the parent 
Figure 5. There is no obvious structural basis for the 
observed epistasis, as none of the epistatically 
interacting mutations are in contact in the solved crystal 
structures of NP. Shown above is one monomer from 
PDB structure 2IQH; the mutations are also not in 
contact in any of the known oligomeric structures 
(Figure 5—figure supplement 1). The sites of the 
three individually deleterious mutations are in orange, 
those of the rescuing mutations are in green, and the 
site of E375G (which can rescue R384G depending on 
genetic background) is in yellow.
DOI: 10.7554/eLife.00631.016
The following figure supplements are available for 
figure 5:
Figure supplement 1. None of the epistatically 
interacting mutations are in contact in the known 
oligomeric structures of NP. 
DOI: 10.7554/eLife.00631.017
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Figure 6. The epistasis correlates with mutational effects on NP stability. (A) and (B) N334H rescues activity and 
mostly rescues viral growth of all three individually deleterious mutations. (C) Western blot showing that the three 
individually deleterious mutations all reduce NP levels in transfected cells relative to an mCherry control expressed 
from an IRES in the same plasmid; this effect is counteracted by N334H. (D) Quantification of NP levels from 
triplicate Western blots (Figure 6—figure supplement 1). (E) The deleterious mutations decrease and N334H 
Figure 6. Continued on next page
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NP—presumably because this parent is already sufficiently stable for its cellular environment. However, 
these stabilizing mutations play a crucial evolutionary role by counteracting the destabilizing muta-
tions and enabling them to fix during evolution.
Of course, we do not wish to caricature protein evolution by suggesting that all epistasis is medi-
ated by stability. In principle, mutations can affect a multitude of properties of NP, including its homo-
oligomerization, association with RNA and other proteins, and cellular transport. We do not suggest 
that these properties are unimportant. In fact, we observe an epistatic interaction between R384G and 
E375G that likely relates to the electrostatic charge on one of NP’s surfaces. Our assays are also of 
finite sensitivity, and so may miss small effects that are still significant to natural selection. There is also 
the potential for epistasis between NP and other viral proteins, although we see no evidence for such 
epistasis here, since all NP evolutionary intermediates that we tested are functional in a fixed back-
ground of other proteins. But doubtless some of these other mechanisms of epistasis would become 
apparent if we examined even longer evolutionary trajectories. However, the overriding message from 
our experiments is that stability-mediated epistasis is the dominant constraint on NP evolution.
Epistatically interacting mutations can be fixed in several ways. The mutations can accumulate 
sequentially without ever passing through a low-fitness intermediate (as in Maynard Smith’s analogy), 
an initial deleterious mutation can be compensated by a subsequent mutation, or multiple mutations 
can occur simultaneously. We have identified two instances that clearly conform to Maynard Smith’s 
paradigm: the stabilizing M136I preceded V280A, and the stabilizing S259L preceded R384G 
(Figure 4B,C). We also identified two instances where the actual evolutionary path is unclear due 
to a lack of natural sequence data from the relevant timeframe: N334H/L259S, and E375G/R384G 
(Figure 4A,B). However, in both cases it is at least possible that evolution conformed to Maynard 
Smith’s paradigm: no simultaneous mutations or deleterious intermediates need have occurred if 
N334H preceded L259S, and if E375G preceded R384G (Figure 4A,B).
increases the stability of NP, as measured by thermal denaturation of purified protein monitored by circular 
dichroism (Figure 6—figure supplements 2–6 and Figure 6—source data 1). Figure 6—figure supplement 7 
shows that M136I, which precedes V280A in the natural evolution, and is modestly stabilizing (Figure 6—figure 
supplements 4–7), also partially rescues the levels of V280A NP in transfected cells and the activity of all three 
individually deleterious mutations. Together, the two stabilizing mutations N334H and M136I can rescue the activity 
of combinations of the individually deleterious mutations (Figure 6—figure supplement 8).
DOI: 10.7554/eLife.00631.018
The following source data and figure supplements are available for figure 6:
Source data 1. A table of all of the melting temperatures and the changes in stability relative to Aichi/1968, in CSV 
format. 
DOI: 10.7554/eLife.00631.019
Figure supplement 1. The full set of triplicate Western blots used to quantify the NP levels in transfected cells. 
DOI: 10.7554/eLife.00631.020
Figure supplement 2. Purification of Aichi/1968 NP with deletion of residues 2–7, mutation R416A, and a 
C-terminal 6-His tag (expected molecular weight 56.6 kDa). 
DOI: 10.7554/eLife.00631.021
Figure supplement 3. Circular dichroism wavelength scans for all variants that were tested (those with thermal 
melts shown in Figure 6—figure supplements 4–6). 
DOI: 10.7554/eLife.00631.022
Figure supplement 4. The first 15 thermal denaturation curves. 
DOI: 10.7554/eLife.00631.023
Figure supplement 5. The second 15 thermal denaturation curves. 
DOI: 10.7554/eLife.00631.024
Figure supplement 6. The last 13 thermal denaturation curves. 
DOI: 10.7554/eLife.00631.025
Figure supplement 7. M136I partially rescues the activity of the three individually deleterious mutations, and 
mostly rescues protein levels for V280A. 
DOI: 10.7554/eLife.00631.026
Figure supplement 8. Activities for NPs with combinations of the stabilizing and destabilizing mutations. 
DOI: 10.7554/eLife.00631.027
Figure 6. Continued
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Figure 7. Most of the epistasis that we identified in NP’s evolution can be explained by counterbalancing stabilizing and destabilizing mutations. 
(A) The relationship between NP stability and transcriptional activity for all variants for which both properties were measured. As long as the stability is 
greater than a threshold around 42°C, changes in stability are neutral with respect to activity. Below this threshold, activity declines sharply with 
decreasing stability. (B) The relationship between viral growth and NP stability exhibits a similar behavior. The exception is that growth of variants with 
R384G is fully rescued only by combining a stabilizing mutation with E375G (Figure 4B), an effect that we hypothesize is related to the electrostatic 
charge on one of NP’s surfaces (Figure 7—figure supplement 1). (C) The dynamics of protein stability during NP evolution. Shown are the measured 
stabilities for evolutionary intermediates from the trajectory in Figure 2A. The lines along the y-axis at the far left show the stabilities of the five indicated 
individual point-mutants of the Aichi/1968 NP. Although the destabilizing mutations L259S, R384G, and V280A are deleterious to the Aichi/1968 parent, 
during evolution they are counterbalanced by stabilizing mutations. In the top panels, selected points are labeled with the NP variant name; the full data 
plotted in this figure are in Figure 7—source data 1.
DOI: 10.7554/eLife.00631.028
The following source data and figure supplements are available for figure 7:
Source data 1. The activity, viral growth, and stability data shown in Figure 7. 
DOI: 10.7554/eLife.00631.029
Figure supplement 1. We hypothesize that E375G helps counteract R348G by maintaining the electrostatic charge on one of NP’s surfaces. 
DOI: 10.7554/eLife.00631.030
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Previous experimental studies have identified 
stabilizing mutations as contributing to the evolu-
tion of enzyme specificities (Bloom et al., 2006), 
bacterial (Wang et al., 2002; Bershtein et al., 
2006; Weinreich et al., 2006) and viral (Chang 
and Torbett, 2011) drug resistance, and H5N1 
transmissibility (Imai et al., 2012). At a broader 
level, analyses of large datasets have shown that 
it is common for mutations to be deleterious to 
one protein homolog but benign to another 
(Kondrashov et al., 2002; Baresic et al., 2010). 
Our work illustrates how the dynamics of stability 
during evolution might explain these findings. As 
shown in Figure 7C, most of the intermediates 
during NP’s evolution are only marginally more 
stable than the minimal threshold where function 
begins to suffer. This marginal stability of natural 
proteins has been noted previously, and been 
given two distinct explanations. The first explana-
tion holds that evolution actively selects for mar-
ginal stability because both insufficient and 
excess stability are deleterious (DePristo et al., 
2005; Tokuriki and Tawfik, 2009). The second 
explanation holds that evolution only selects 
against insufficient stability, but that proteins typ-
ically are marginally stable because most muta-
tions are destabilizing and so extra stability is 
rapidly eroded by functionally neutral but desta-
bilizing mutations (Taverna and Goldstein, 2002; 
Bloom et al., 2007). Our results decisively favor 
the second explanation for NP, since the evolving 
protein is usually marginally stable despite the 
fact that higher stability has no deleterious effect 
(Figure 7A,B). We therefore suggest the fol-
lowing: functionally neutral but stabilizing muta-
tions occasionally fix by stochastic forces such as 
genetic drift, population bottlenecks, or hitchhik-
ing. These stabilizing mutations enable NP to tol-
erate otherwise deleterious destabilizing 
mutations. Although these destabilizing muta-
tions could in principle also fix by stochastic 
forces, the three that we have identified are actu-
ally adaptive since they contribute to viral im-
mune escape. Stability-mediated epistasis 
therefore constrains NP’s adaptation as well as its 
sequence evolution, since the accessibility of 
immune-escape mutations is dependent on the 
acquisition of enabling mutations.
It is intriguing to speculate whether similar 
forms of epistasis might constrain the evolution 
of other proteins. For example, the antigenic ev-
olution of influenza hemagglutinin is punctuated, 
with a fairly constant rate of sequence change 
nonetheless leading to periodic jumps in anti-
genicity that require reformulation of the annual 
influenza vaccine (Smith et al., 2004). One 
Figure 8. The three epistatically constrained destabiliz-
ing mutations occur at sites significantly enriched in 
human CTL epitopes. Distributions of the numbers of 
experimentally characterized epitopes per residue for 
all sites or sites that experienced mutations along the 
evolutionary trajectory are in blue and red, respectively. 
Sites 259, 280, and 384 are in significantly more 
epitopes than three random positions from all sites 
(p=0.001) or the mutated sites (p=0.004); however, three 
random positions from the mutated sites are not in 
significantly more epitopes than three random positions 
from all sites (p=0.157). Epitopes with experimentally 
characterized CTL responses were mined from the 
Immune Epitope Database (Figure 8—source code 1 
and Figure 8—figure supplement 1). The primary 
citation and summary information for epitopes  
involving sites 259, 280, and 384 are in Figure 8—
source data 1. Similar results are obtained if CTL 
epitopes are instead predicted computationally  
(Figure 8—figure supplements 1, 2). A dN/dS analysis 
is inconclusive about whether the three sites are under 
positive or negative selection, probably due to lack of 
sequence data (Figure 8—figure supplement 3 and 
Figure 8—source code 2).
DOI: 10.7554/eLife.00631.031
The following source data, source code and figure 
supplements are available for figure 8:
Source data 1. Literature-characterized NP human CTL 
epitopes that include residues 259, 280, or 384 and 
contain sequences conserved or nearly conserved in 
Aichi/1968. 
DOI: 10.7554/eLife.00631.032
Source code 1. The input data files and the custom 
Python scripts used to identify human CTL epitopes in 
NP. 
DOI: 10.7554/eLife.00631.033
Source code 2. The data and source code used for the 
dN/dS analysis. 
DOI: 10.7554/eLife.00631.034
Figure supplement 1. Distribution of human CTL 
epitopes along the NP primary sequence. 
DOI: 10.7554/eLife.00631.035
Figure 8. Continued on next page
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explanation that has been posited for this punc-
tuated pattern is that adaptive antigenic change 
is limited not by the overall rate of substitution, 
but rather by the waiting time for the protein to 
accumulate antigenically neutral mutations that 
can be productively combined with mutations 
causing large antigenic changes (Koelle et al., 
2006; van Nimwegen, 2006). Stability-mediated 
epistasis of the type that we have observed for 
NP provides at least one plausible mechanistic 
explanation for this and other cases of con-
strained molecular evolution.
Materials and methods
Evolutionary trajectory
Via Markov chain Monte Carlo implemented in BEAST (Drummond et al., 2012), we estimated the 
joint posterior distribution of phylogenetic trees and mutations along the branches of these trees 
given 431 date-stamped human H3N2 NP protein sequences from the Influenza Virus Resource. We 
assumed a Jones—Taylor—Thornton model (Jones et al., 1992) of protein substitution, a strict molec-
ular clock and a relatively uninformative coalescent-based prior on the tree. We inferred the unob-
served mutations via a data augmentation procedure that exploits uniformization and is robust to 
model misspecification (Minin and Suchard, 2008; O’Brien et al., 2009). Figure 2B reports the max-
imum clade credible tree from the posterior distribution.
Novel to this work, for each posterior sample, we converted the order of mutations along the line 
of descent from Aichi/1968 and Brisbane/2007 into a directed graph through sequence space 
(Figure 2—figure supplement 1). Summarizing these graph samples effectively integrates over 
uncertainty in the tree and substitution process, returning the marginal posterior distribution of the 
evolutionary trajectory of interest. In our GraphViz visualization, each circle represents a unique 
inferred sequence. Areas and intensities of circles are proportional to the posterior probability that 
the true trajectory visited that sequence. Lines correspond to mutations, with thickness and intensity 
proportional to the posterior probability that specific mutation connected those two sequences. We 
labeled connections with posterior probability ≥60% in black in Figure 2; mutations lacking high-
confidence connections are in red. Likewise, we considered sequences with posterior probability 
≥60% as high confidence and assigned them numeric labels. Figure 2—source code 1 contains the 
relevant computer code.
Transcriptional activity
We reverse-transcribed the Aichi/1968 NP and the Nanchang/1995 PB2, PB1, and PA from viral 
RNA (BEI Resources NR-9534 and NR-3222), and cloned them into pHW2000 (Hoffmann et al., 
2000) (a gift from Y Kawaoka) to create pHWAichi68-NP, pHWNan95-PB2, pHWNan95-PB1, and 
pHWNan95-PA (Supplementary file 1). Similar plasmids were constructed for the PB2, PB1, and 
PA of Aichi/1968 and Brisbane/2007 and named pHWAichi68-PB2, pHWAichi68-PB1, pHWAichi68-PA, 
pHWBR07-PB2, pHWBR07-PB1, and pHWBR07-PA (Supplementary file 1). We used site-directed 
mutagenesis to create the other NP variants (Supplementary file 2). Note that the final sequence 
at the end of our trajectory (Step 39) matches the Brisbane/2007 protein sequence, but does not 
match the nucleotide sequence of this strain as we did not introduce any of the synonymous 
mutations.
We measured activity using a previously described (Bloom et al., 2010) reporter plasmid encoding 
a GFP vRNA with termini from the A/WSN/1933 PB1. We co-transfected this reporter into 12-well 
dishes of 293T cells along with 50 ng of NP plasmid and 200 ng each of pHWNan95-PB2, pHWNan95-
PB1, and pHWNan95-PA (Figure 3—figure supplement 1). This amount of NP plasmid is near the 
midpoint of the dose-response curve (Figure 3—figure supplement 1). After 20 hr, we quantified the 
GFP mean-fluorescence intensity (MFI) by flow cytometry. We seeded 293T cells at 2 × 105 per well 
20–24 hr pre-transfection in D10 (DMEM with 10% heat-inactivated fetal bovine serum, 2 mM L-glutamine, 
100 U/ml penicillin, and 100 μg/ml streptomycin). We quantified the activity relative to the average 
Figure supplement 2. The three epistatically con-
strained mutations are at sites significantly enriched in 
CTL epitopes as predicted by a computational epitope 
prediction program NetCTLpan1.1. 
DOI: 10.7554/eLife.00631.036
Figure supplement 3. It is largely inconclusive whether 
the sites of the three epistatically constrained mutations 
are under positive or negative selection as quantified 
by dN/dS values. 
DOI: 10.7554/eLife.00631.037
Figure 8. Continued
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for three replicates of wild-type pHWAichi68-NP. We performed at least three biological replicates for 
each variant, with each replicate performed on a different day using an independent plasmid mini-
prep. Figure 3—source data 1 gives the means and standard errors of the activities for all NP 
variants.
Viral growth
We grew viruses carrying GFP in the PB1 gene using a modification of a previously described system 
(Bloom et al., 2010; Figure 3—figure supplement 2). We used lentiviral transduction to create the 
cell lines 293T-CMV-Nan95-PB1 and MDCK-SIAT1-CMV-Nan95-PB1, which express the coding 
sequence of the Nanchang/1995 PB1 with the F2 peptide disrupted after its eighth codon (Chen 
et al., 2001) under control of a CMV promoter. We seeded co-cultures of 2 × 105 293T-CMV-Nan95-PB1 
and 2 × 104 MDCK-SIAT1-CMV-Nan95-PB1 cells in D10 media in six-well dishes, and 20–24 hr later 
transfected with 250 ng each of pHWNan95-PB2, pHH-PB1flank-eGFP (Bloom et al., 2010), 
pHWNan95-PA, a pHWAichi68-NP variant, pHW184-HA, pHW186-NA, pHW187-M, and pHW188-
NS. These last four plasmids (Hoffmann et al., 2000) encode genes from A/WSN/1933 (gifts from 
Y Kawaoka). After 20–24 hr, we replaced the D10 with influenza growth media (Opti-MEM I with 0.3% 
BSA, 0.01% heat-inactivated fetal bovine serum, 100 U/ml penicillin, 100 μg/ml streptomycin, and 
100 μg/ml calcium chloride). After 66 hr (shortly before peak titers, Figure 3—figure supplement 2), 
we collected the supernatant and clarified it for 5 min at 2000×g. We infected dilutions of supernatant 
into 12-well dishes seeded 8 hr earlier at 105 MDCK-SIAT1-CMV-Nan95-PB1/well in influenza growth 
media, and 16 hr later determined the titer by flow cytometry by using the Poisson equation to 
estimate the viral titer based on the fraction of GFP positive cells. We performed these titering infec-
tions with various volumes of viral supernatant such that the titer could be computed from an infection 
with between 0.5% and 10% of cells green. Note that these titers reflect the number of particles that 
are able to productively infect cells and transcribe high levels of GFP from viral RNA—they may not 
reflect the same titers as would be determined using other approaches such as plaque assays or tissue-
culture infectious dose 50% assays. We quantified the titer relative to the average of three replicates 
of the wild-type pHWAichi68-NP (typically around 103 infectious particles per microliter). We per-
formed at least three biological replicates for each variant, with each replicate performed on a dif-
ferent day using an independent plasmid mini-prep. Figure 3—source data 2 gives the means and 
standard errors.
NP protein levels
We cloned the NP coding sequence into a mammalian expression plasmid under control of a CMV 
promoter with a FLAG tag inserted between the N-terminal methionine and the second residue. 
After the NP stop codon, we added an internal ribosome entry site (IRES) followed by mCherry 
with a C-terminal FLAG tag. We seeded 293T cells at 2 × 105 per well in D10 in 12-well dishes, and 
20–24 hr later transfected with 400 ng of plasmid. After 20 hr, we collected the cells and lysed 
them on ice in 100 μl of RIPA buffer with one protease-inhibitor tablet (Roche, Basel, Switzerland, 
05892791001) per 10 ml. We pelleted debris at 21,000×g for 10 min, and loaded 2.5 μl of clarified 
supernatant on an SDS-PAGE gel after boiling with a reducing sample-loading buffer. We transferred 
the protein to a PVDF membrane and stained with a 1:5000 dilution of mouse anti-FLAG (Sigma, 
St. Louis, MO, F1804) followed by a 1:2500 dilution of Alexa Flour 680-conjugated goat anti-mouse 
(Invitrogen, Grand Island, NY, A-21058), using Li-Cor Odyssey (Lincoln, NE) blocking buffer (Li-Cor 
927-40,000) and performing washes with TBS-T (Pierce, Rockford, IL, 28360). We quantified the ratio 
of NP to the corresponding mCherry control using a Li-Cor Odyssey Infrared Imaging System, and 
normalized this ratio to that for wild-type Aichi/1968 NP (Figure 6—figure supplements 1, 7).
Protein stability
In order to obtain non-aggregated RNA-free NP in a CD-compatible buffer, we introduced two previ-
ously described (Ye et al., 2006) modifications: deletion of residues 2–7 and R416A. We cloned NP 
with these modifications and a C-terminal 6-histidine tag into pET28b(+), transformed into BL21 Star 
DE3 (Invitrogen, Grand Island, NY, C6010-03), and grew 1 L of these bacteria to an OD600 of 0.3–0.6 
at 37°C. We then chilled the cultures on ice, reduced the shaker temperature to 20°C and induced with 
500 μM IPTG. After overnight growth, we pelleted the cells and lysed them on ice by sonication in 
50 ml of 50 mM sodium phosphate pH 8.0, 500 mM sodium chloride, 0.5% Triton X-100, 10 mM imid-
azole, 1 mM PMSF, 0.1 mg/ml magnesium chloride, 1 mM lysozyme, and 1000 units of benzonase 
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(Sigma, St. Louis, MO, E1014). We clarified the supernatant for 30 min at 10,000×g and 4°C, passed it 
through a 0.45-μm filter, and purified NP over a cobalt column (Pierce, Rockford, IL, 89969) using the 
manufacturer’s protocol but eluting with 200 mM imidazole. We concentrated the protein with an 
Amicon Ultra 30 kDa filter, and dialyzed it against CD buffer (20 mM sodium phosphate pH 7.0 with 
300 mM sodium fluoride) in a 20-kDa dialysis device. We further purified the protein over a Superdex 
200 GL size-exclusion column. All variants eluted in a single monomeric peak, and all had ratios of 
absorbance at 260 nm to absorbance at 280 nm of less than 0.65 (Figure 6—figure supplement 2).
We diluted the proteins to 5 μM in CD buffer as determined by the absorbance at 280 nm in a 
1 cm quartz cuvette using an extinction coefficient of 0.0566 μM/cm, and acquired CD spectra at 
20°C with a Jasco J-815 spectropolarimeter. All variants exhibited similar spectra with typical 
alpha-helical characteristics (Figure 6—figure supplement 2, 3). We performed thermal melts at 
a scan rate of 2°C per minute, monitoring ellipticity at 209 nm. All variants unfolded with a single 
cooperative transition, allowing us to obtain melting temperatures from sigmoidal curve fits 
(Figure 6—figure supplements 4–6 and Figure 6—source data 1). The melting was irreversible 
(Figure 6—figure supplement 2), preventing us from calculating equilibrium thermodynamic 
stabilities.
CTL epitopes
We identified human CTL epitopes of ≤12 residues with at least 89% conservation in Aichi/1968 
NP and a verified T-cell response from the Immune Epitope Database (Vita et al., 2010). Figure 8—
source data 1 lists primary citations for epitopes involving residues 259, 280, and 384. Figure 8—
figure supplement 1 shows the number of epitopes at each position. We computed p-values by 
randomly drawing three different residues from the set of all sites or all mutated sites, and 
comparing the number of epitopes for these sites to the number for sites 259, 280, and 384 
(Figure 8). p-values represent the fraction of 105 random draws that contained at least as many 
epitopes as sites 259, 280, and 384. We performed a similar analysis for epitopes predicted by 
NetCTLpan 1.1 (Stranzl et al., 2010) using the default settings for 9-mer peptides and the HLA 
supertypes (Figure 8—figure supplement 2). The data and computer code are in Figure 8—
source code 1.
The dN/dS comparisons shown in Figure 8—figure supplement 3 were performed with FUBAR 
(Murrell et al., 2013) using the DataMonkey server. The sequence data, results, and analysis are in 
Figure 8—source code 2.
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genetics plasmids pHWAichi68-NP, pHWNan95-PB2, pHWNan95-PB1, pHWNan95-PA, pHWAichi68-
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pHW186-NA, pHW187-M, pHW188-NS, and pHH-PB1flank-eGFP.
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